HANSOH PHARMA(03692)

31.540-0.640-1.99%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Hansoh Pharmaceutical Group Stock Sheds 2.0% in Hong Kong
  Dow Jones · 10-09 16:33
  Hansoh Pharmaceutical Group Stock Sheds 2.0% in Hong Kong
- Hansoh Pharmaceutical Group Stock Falls 5.1% in Hong Kong
  Dow Jones · 10-08 16:31
  Hansoh Pharmaceutical Group Stock Falls 5.1% in Hong Kong
- Movement Alert｜HANSOH PHARMA Falls 3.01% in Regular Trading, Major Shareholder Affiliates Reduced Stakes and EU Marketing Revocation for Aumolertinib
  Market Focus · 10-08
  Movement Alert｜HANSOH PHARMA Falls 3.01% in Regular Trading, Major Shareholder Affiliates Reduced Stakes and EU Marketing Revocation for Aumolertinib
- Does China Cancer Drug Filing Change The Bull Case For Hansoh Pharmaceutical Group (SEHK:3692)?
  Simply Wall St. · 10-07
  Does China Cancer Drug Filing Change The Bull Case For Hansoh Pharmaceutical Group (SEHK:3692)?
- Hansoh Pharmaceutical Group Stock Rises 1.7% in Hong Kong
  Dow Jones · 10-06
  Hansoh Pharmaceutical Group Stock Rises 1.7% in Hong Kong
- Cantrust (Far East) Limited Cuts Stake in Hansoh Pharma (03692) by 124,000 Shares at About HK$33.96 Each
  Stock News · 10-05
  Cantrust (Far East) Limited Cuts Stake in Hansoh Pharma (03692) by 124,000 Shares at About HK$33.96 Each
- HANSOH PHARMA: JQC International Limited Disposes of Shares, Long Position Falls to 15.16%
  HK Disclosure · 10-05
  HANSOH PHARMA: JQC International Limited Disposes of Shares, Long Position Falls to 15.16%
- HANSOH PHARMA: Junda Cen Disposes of Shares, Long Position Falls to 15.16%
  HK Disclosure · 10-05
  HANSOH PHARMA: Junda Cen Disposes of Shares, Long Position Falls to 15.16%
- HANSOH PHARMA: APEX MEDICAL COMPANY LTD. Disposes of Shares, Long Position Falls to 15.16%
  HK Disclosure · 10-05
  HANSOH PHARMA: APEX MEDICAL COMPANY LTD. Disposes of Shares, Long Position Falls to 15.16%
- HANSOH PHARMA: JQC Holding Limited Disposes of Shares, Long Position Falls to 15.16%
  HK Disclosure · 10-05
  HANSOH PHARMA: JQC Holding Limited Disposes of Shares, Long Position Falls to 15.16%
- Hansoh Pharma Says Phase III Lighten Trial Shows 19.3% Weight Loss at Week 48 with Olatorepatide 15 Mg
  Reuters · 10-05
  Hansoh Pharma Says Phase III Lighten Trial Shows 19.3% Weight Loss at Week 48 with Olatorepatide 15 Mg
- Major Drugmakers Turn to China for Licensing Deals
  Reuters · 10-02
  Major Drugmakers Turn to China for Licensing Deals
- Hansoh Pharmaceutical Group Stock Slips 3.3% in Hong Kong
  Dow Jones · 10-02
  Hansoh Pharmaceutical Group Stock Slips 3.3% in Hong Kong
- Hansoh Pharmaceutical Group (SEHK:3692) Could Be 30% Undervalued On Late Stage Drug Progress
  Simply Wall St. · 10-02
  Hansoh Pharmaceutical Group (SEHK:3692) Could Be 30% Undervalued On Late Stage Drug Progress
- Movement Alert｜HANSOH PHARMA Falls 3.97% in Regular Trading, EU Revocation of Aumolertinib Approval Continues to Weigh on Sentiment
  Market Focus · 10-02
  Movement Alert｜HANSOH PHARMA Falls 3.97% in Regular Trading, EU Revocation of Aumolertinib Approval Continues to Weigh on Sentiment
- Major Drugmakers Turn to China for Licensing Deals
  Reuters · 09-30
  Major Drugmakers Turn to China for Licensing Deals
- Hansoh Pharmaceutical Group Stock Rises 5.3% in Hong Kong
  Dow Jones · 09-30
  Hansoh Pharmaceutical Group Stock Rises 5.3% in Hong Kong
- Movement Alert｜HANSOH PHARMA Rises 3.16% in Regular Trading, Competitor B7-H3 ADC Withdrawal Boosts Outlook Amid Sector Rally
  Market Focus · 09-30
  Movement Alert｜HANSOH PHARMA Rises 3.16% in Regular Trading, Competitor B7-H3 ADC Withdrawal Boosts Outlook Amid Sector Rally
- EU Withdrawal of Aumseqa Exposes Hansoh Pharma's Compliance Gaps and Global Ambitions
  Deep News · 09-29
  EU Withdrawal of Aumseqa Exposes Hansoh Pharma's Compliance Gaps and Global Ambitions
- JPMorgan: Merck/Daiichi Sankyo Withdrawal of B7-H3 ADC Filing Is a Positive for Hansoh Pharma/GSK's Ris-Rez
  Stock News · 09-28
  JPMorgan: Merck/Daiichi Sankyo Withdrawal of B7-H3 ADC Filing Is a Positive for Hansoh Pharma/GSK's Ris-Rez
Company Profile
Company Name
HANSOH PHARMA
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
- -
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.
- 09-23
  Interim Report
  INTERIM REPORT 2026
  INTERIM REPORT 2026
- 08-26
  Interim Report
  INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2026
  INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2026
- 04-28
  Annual Report
  ANNUAL REPORT 2025
  ANNUAL REPORT 2025

1D
5D
Day
Week
Month

Loading ...

High

32.860

Open

32.380

Volume%

1.25

Low

31.180

32.180

T/O Rate

0.16%

To The Moon

HANSOH PHARMA(03692)

Company Profile

Most Discussed